Ecopipam hydrochloride
Modify Date: 2025-09-09 14:52:27
Ecopipam hydrochloride structure
|
Common Name | Ecopipam hydrochloride | ||
|---|---|---|---|---|
| CAS Number | 190133-94-9 | Molecular Weight | 350.28200 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C19H21Cl2NO | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Ecopipam hydrochlorideEcopipam (SCH 39166) hydrochloride is a potent, selective and orally active antagonist of dopamine D1/D5 receptor, with Kis of 1.2 nM and 2.0 nM, respectively. Ecopipam hydrochloride shows more than 40-flod selectivity over D2, D4, 5-HT, and α2a receptor (Ki=0.98, 5.52, 0.08, and 0.73 μM, respectively). Ecopipam hydrochloride can be used for the research of schizophrenia, cocaine addition, and obesity[1][3]. |
| Name | (6aS,13bR)-11-Chloro-7-methyl-6,6a,7,8,9,13b-hexahydro-5H-benzo[d ]naphtho[2,1-b]azepin-12-ol hydrochloride (1:1) |
|---|
| Description | Ecopipam (SCH 39166) hydrochloride is a potent, selective and orally active antagonist of dopamine D1/D5 receptor, with Kis of 1.2 nM and 2.0 nM, respectively. Ecopipam hydrochloride shows more than 40-flod selectivity over D2, D4, 5-HT, and α2a receptor (Ki=0.98, 5.52, 0.08, and 0.73 μM, respectively). Ecopipam hydrochloride can be used for the research of schizophrenia, cocaine addition, and obesity[1][3]. |
|---|---|
| Related Catalog | |
| Target |
D1 Receptor:1.2 nM (Ki) D5 Receptor:2.0 nM (Ki) D2 Receptor:980 nM (Ki) D4 Receptor:5520 nM (Ki) 5-HT Receptor:80 nM (Ki) Alpha-2A adrenergic receptor:731 nM (Ki) |
| In Vitro | Ecopipam (2 μM) hydrochloride completely abolishes the proconvulsive effect of Dopamine (10 μM) in isolated corticohippocampal formation[2]. |
| In Vivo | Ecopipam (0.003-0.3 mg/kg, a single s.c.) hydrochloride abolishes Nicotine-induced enhancement of a sensory reinforcer in adult rats[3]. Ecopipam (10, mg/kg, oral administration) hydrochloride antagonizes Apomorphine-induced stereotypy in rats[4]. Ecopipam (5 and 10 μM, perfusion, 1 μL/min) hydrochloride reversibly and dose-dependently decreases acetylcholine release in the rat striatum[5]. Animal Model: Male young adult Long-Evans rats injected with Nicotine[3] Dosage: 0.003, 0.01, 0.03, 0.1, 0.3 mg/kg Administration: A single s.c. 20 min before Nicotine (0.1 mg/kg) Result: Dose-dependently reduced pressing on both active and inactive levers. |
| References |
| Molecular Formula | C19H21Cl2NO |
|---|---|
| Molecular Weight | 350.28200 |
| Exact Mass | 349.10000 |
| PSA | 23.47000 |
| LogP | 4.72010 |
| InChIKey | APFMVAHRFWBCDG-JUOYHRLASA-N |
| SMILES | CN1CCc2cc(Cl)c(O)cc2C2c3ccccc3CCC21.Cl |